drugset

drugset / Trial / NCT05111509

A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent

NCT05111509 ↗

Phase 0 Active not recruiting 20 enrolled Yusuf Menda Holden Comprehensive Cancer Center · collab National Cancer Institute (NCI) · collab Perspective Therapeutics · collab

NaSingle-groupOpen-labelDiagnostic

Summary

This is a first in man study to determine if \[203Pb\]VMT-α-NET identifies neuroendocrine tumors with SPECT/CT. This is the first step to testing \[212Pb\]-based alpha radiation therapy in neuroendocrine therapy.

Timeline

Start: 2022-08-22
Primary completion: 2026-04-30
Completion: 2026-06-30

Publications

Graves SA, Bushnell DL, Schultz MK, Jain S, Bodeker KL, Menda Y. A Phase 0 Imaging Trial of [203Pb]Pb-VMT-alpha-NET to Enable Dosimetry and Treatment Planning for Refractory or Relapsed Metastatic Neuroendocrine Tumors with [212Pb]Pb-VMT-alpha-NET. J Nucl Med. 2026 Apr 1;67(4):576-583. doi: 10.2967/jnumed.125.270083.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	[203Pb]VMT-α-NET	Diagnostic / imaging agent	3 unknown	Intravenous
Subject	[203Pb]VMT-α-NET	Diagnostic / imaging agent	5 unknown	Intravenous

Indications